Overview

Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Chronic Graft Versus Host Disease

Status:
Unknown status
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to evaluate the safety and efficacy of mesenchymal stem cells (MSC) for the treatment of patients who have developed an extensive chronic graft versus host disease (with skin and/or liver damage) after HSCs transplantation and do not respond to first-line therapy. The secondary purpose of the study is to evaluate the effect of mesenchymal stem cells (MSC) on one-year survival rate, long-term survival rate, life quality and recurrence of patients who have developed an extensive chronic graft versus host disease (with skin and/or liver damage) after HSCs transplantation and do not respond to hormone treatment.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Chinese Academy of Medical Sciences
Collaborators:
307 Hospital of PLA
Chinese PLA General Hospital
Peking Union Medical College
Zhejiang University
Treatments:
Cyclosporine
Cyclosporins
Glucocorticoids